These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Current developments in the use of prostaglandins for induction of abortion.
    Author: Wiqvist N, Bygdeman M, Toppozada M.
    Journal: Res Prostaglandins; 1972 Nov; 2(3):1-4. PubMed ID: 12336859.
    Abstract:
    Intravenous doses of prostaglandins used in induction of abortion have associated side effects (nausea, vomiting, diarrhea, pyrexia, shivering, and local erythema at site of venipuncture). Another mode of administration, the vaginal administration, is known to stimulate uterine contractility effectively, as shown by a 100% success rate in a clinical abortion trial of 45 women (Karim and Sharma). Brenner et al. and Beguin et al. however reported a high incidence of side effects with this approach. The intrauterine route of administration appears to be the method of choice for inducing 2nd trimester abortion because of low incidence of side effects. Total dose required for abortion induction by the extraamniotic method is about 10 to 20 times lower than the intravenous dose. A review of the literature on extraamniotic method reveals that the most common technic of administration includes repeated injections of PGF2a (250-750 mcg) or PGE2 (50-200 mcg) at 2 hourly intervals via a self-retaining Foley catheter introduced through the cervix into the lower uterine segment. Reported success rates with this method are 87% (Embrey et al.) and 90% (Bygdeman). Various dose schedules of prostaglandins result in varying success rates, injection-abortion interval, and incidence of side effects. The difficulties of terminating late 1st trimester pregnancies and early 2nd trimester of pregnancies are briefly discussed.
    [Abstract] [Full Text] [Related] [New Search]